Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabien Tech. Regulatory News (SNT)

Share Price Information for Sabien Tech. (SNT)

Share Price is delayed by 15 minutes
Get Live Data
3.25    0.00 (0.00%)
Bid:
3.00
Ask:
3.50
Spread: 0.50 (16.667%)
Market Cap: £1.03m
SNT Live PriceLast checked at - London Stock Exchange

Intraday Sabien Tech. Share Chart

Year End Trading Update

Today 07:00

RNS Number : 0169M
Sabien Technology Group PLC
13 July 2026
 

The information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation.

13 July 2026

Sabien Technology Group plc

("Sabien", the "Company" or the "Group")

Year End Trading Update

 

Sabien (AIM: SNT), a provider of energy efficiency technologies through its M2G intelligent boiler optimisation platform, provides a trading update ahead of the publication of its audited results for the year ended 30 June 2026 ("FY2026").

During FY2026 the Company focused on transforming Sabien into a higher-margin technology business centred on its M2G Cloud Connect platform, whilst strengthening its balance sheet and evaluating strategic opportunities to accelerate long-term shareholder value.

Trading

The M2G platform enables operators of commercial gas boilers to reduce energy consumption and carbon emissions by between 10% and 30%, typically delivering customers with a payback period of less than twelve months.

Customer orders received during FY2026 totalled over £908,000 (FY2025: £948,053), demonstrating resilient customer demand despite a challenging capital expenditure environment.

Revenue recognised during FY2026 is expected to be over £746,000 (FY2025: £846,015), subject to completion of the audit process.

Revenue recognised during the second half of the financial year principally reflected the timing of customer installation programmes, with a number of orders received in the period carried forward into FY2027 revenue.

The Company enters FY2027 with confirmed customer orders of over £196,000, compared with £59,453 at the beginning of FY2026, providing materially improved revenue visibility entering the new financial year.

Balance Sheet

During the year the Company completed several initiatives to strengthen its balance sheet, including the repayment of one of the loans previously provided by Parris Group Limited, as announced on 2 June 2026.

The Board believes these actions have materially improved the Company's financial position and provide a stronger platform from which to execute its commercial strategy.

Strategic Review

As announced on 21 May 2026, the Board commenced a review of strategic initiatives intended to accelerate long-term shareholder value.

The review has included discussions regarding potential strategic investment and commercial partnership opportunities intended to accelerate deployment of the M2G platform and support the Company's long-term growth strategy.

Those discussions remain ongoing. No agreement has been reached and there can be no certainty that any transaction will ultimately proceed.

The Board is evaluating alternative structures and will only pursue a transaction where it believes the commercial terms appropriately reflect the long-term strategic value of the Company, maintain an appropriate balance of commercial risk and reward, and are demonstrably in the best interests of all shareholders.

The strategic review has reinforced the Board's confidence in the long-term value of the Company's technology and in its ability to create shareholder value through continued independent execution, commercial partnerships or broader strategic relationships.

Accordingly, the Board's priorities remain focused on:

· expanding commercial routes to market;

· completing the migration of the M2G platform to the EVO architecture;

· improving operational leverage and cash generation; and

· maintaining disciplined capital allocation to maximise long-term shareholder value.

COF / b.grn

The Board continues to review the Company's investment in b.grn Group Limited and associated commercial arrangements relating to City Oil Field ("COF").

Whilst the Company's principal strategic focus remains the growth of its M2G business, the Board believes it is appropriate to preserve strategic flexibility in relation to its COF-related interests whilst its review continues.

Accordingly, the Board believes it is in shareholders' best interests to complete its review only once it has sufficient clarity to determine the long-term structure that best maximises shareholder value.

Richard Parris, Executive Chairman, commented:

"The past year has been one of disciplined execution. We have strengthened the Company's balance sheet, maintained resilient customer demand and entered FY2027 with a significantly stronger opening order book.

Over recent months the Board has carefully evaluated various strategic alternatives capable of accelerating shareholder value. Our responsibility is to ensure that any strategic transaction appropriately reflects the long-term strategic value of the Company, maintains an appropriate balance of commercial risk and reward, and delivers a superior outcome for shareholders compared with continued disciplined execution of our strategy.

Our priorities remain unchanged. We will continue to broaden our commercial routes to market, complete the migration of the M2G platform to the EVO architecture, improve operational efficiency and maintain disciplined capital allocation as we build a stronger and more scalable business.

Sabien today is a stronger business than it was twelve months ago. We have a stronger balance sheet, greater visibility entering the new financial year and a clearer strategic focus. That disciplined approach also extends to preserving strategic flexibility where the Board believes doing so has the potential to maximise long-term shareholder value."

For further information

Sabien Technology Group plc

Richard Parris, Executive Chairman

+44 (0)20 7993 3700

investors@sabien.com

Allenby Capital Limited (Nominated Adviser)

John Depasquale / Nick Harriss / Vivek Bhardwaj

+44 (0)20 3328 5656

AlbR Capital Limited (Broker)

Duncan Vasey / Lucy Williams

+44 (0)20 7469 0930

About Sabien Technology Group plc

Sabien Technology Group plc develops technologies that help organisations reduce energy consumption, lower carbon emissions and improve building efficiency through intelligent energy optimisation technologies.

The Company holds the London Stock Exchange's Green Economy Mark, recognising listed companies deriving more than 50% of revenues from products and services supporting the global green economy.

Website: www.sabien.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTRTMFTMTABBAF
Date   Source Headline
19th Feb 20247:30 amRNSHalf-year Report for the 6 months to 31 Dec 2023
7th Feb 20247:00 amRNSNew system installed at Hampton Court Palace
9th Jan 20247:00 amRNSTrading Update
29th Nov 20231:00 pmRNSResult of AGM
29th Nov 20237:30 amRNSAGM Statement
21st Nov 20231:30 pmRNSHolding(s) in Company
3rd Nov 20234:50 pmRNSHolding(s) in Company
2nd Nov 20231:34 pmRNSHolding(s) in Company
2nd Nov 20237:00 amRNSFinal Results & Annual Report & Accounts for 2023
1st Nov 20237:15 amRNSUpdate on 2023 Audited Accounts
4th Oct 20237:00 amRNSM2G Rollout in US
26th Sep 20237:00 amRNSProton Technologies
22nd Sep 20236:00 pmRNSHolding(s) in Company
6th Jul 20237:00 amRNSTrading Update
8th Jun 20237:00 amRNSM2G Business Update
16th May 20237:00 amRNSFurther update on b.grn and related matters
17th Apr 20237:00 amRNSUpdate on b.grn
13th Apr 20239:15 amRNSHolding(s) in Company
6th Apr 20237:00 amRNSDirector/PCA Shareholding
5th Apr 20235:00 pmRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSInterim Results for the 6 months to 31 Dec 2022
28th Mar 20237:00 amRNSMaterial M2G Order & Business Update
27th Mar 20237:00 amRNSM2G supports Empiric on net zero goals
10th Mar 202311:33 amRNSHolding(s) in Company
10th Mar 202311:30 amRNSHolding(s) in Company
10th Mar 20237:00 amRNSMaterial M2G order and M2G trading update
28th Feb 20232:45 pmRNSHolding(s) in Company
6th Feb 20234:30 pmRNSHolding(s) in Company
2nd Feb 20234:51 pmRNSHolding(s) in Company
22nd Nov 202212:00 pmRNSResult of AGM
22nd Nov 20227:30 amRNSInvestor Update & Annual General Meeting Statement
18th Nov 20221:46 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSInvestor Update Presentation
2nd Nov 20227:00 amRNSSupply of UK's First Regenerative Green Oil System
24th Oct 20227:00 amRNSOrder Update – New Channel Partner & Customer
17th Oct 20222:47 pmRNSHoling(s) in Company
17th Oct 20221:54 pmRNSHolding(s) in Company
17th Oct 20227:00 amRNSHoling(s) in Company
17th Oct 20227:00 amRNSInternational Environmental Trae Summit Upate
17th Oct 20227:00 amRNSInternational Environmental Trade Summit Update
17th Oct 20227:00 amRNSHolding(s) in Company
14th Oct 20227:00 amRNSFinal Results for the Year to 30 June 2022
12th Oct 20227:00 amRNSHolding(s) in Company
5th Oct 20223:33 pmRNSHolding(s) in Company
23rd Sep 20222:49 pmRNSHolding(s) in Company
20th Sep 20224:16 pmRNSHolding(s) in Company
16th Sep 20227:00 amRNSRevised Date for Summit for S'th Korean Delegation
31st Aug 20225:00 pmRNSTotal Voting Rights
25th Aug 20223:30 pmRNSAdmission to trading of new Ordinary Shares
22nd Aug 20226:24 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.